Treatment of patients aged over 50 years with non-osseous Ewing’s sarcoma family tumors: five cases and review of literature

Gil Bar-Sela¹, Avivit Peer¹, Shelly Rothschild², and Nissim Haim¹

¹Division of Oncology, Rambam-Health Care Campus, and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa; ²Department of Family Medicine, Clalit Health Services, Haifa and Western Galilee District, Israel

ABSTRACT

Background. Most clinical trials on Ewing’s sarcoma family of tumors include pediatric and adolescent populations, whereas clinical data on older patients are limited.

Patients and methods. We report on 5 patients older than 50 years with a tumor of the Ewing's sarcoma family treated recently in our department.

Results. Myelosuppression and infectious complications were the main toxicity encountered. Major dose reductions and/or treatment delays were required in all 5 patients. One patient died of septic shock. Complete remission was achieved in the remaining 4 patients with the addition of different treatment modalities. One patient had lung metastasis 3 years after starting chemotherapy, and 3 patients have remained without evidence of recurrent disease for 1-6 years from the onset of chemotherapy.

Conclusions. There is no definite answer as to whether older age is a poor prognostic factor in patients with a tumor of the Ewing's sarcoma family. In our experience, patients over 50 poorly tolerated the standard chemotherapy protocol used in the pediatric population.

Key words: Ewing's sarcoma family tumors, older population, prognostic factor.

Correspondence to: Dr Gil Bar-Sela, Division of Oncology, Rambam-Health Care Campus, POB 9602, Haifa 31096 Israel.
Tel 972-4-854-3810;
fax 972-4-854-2929;
e-mail g_barsela@rambam.health.gov.il

Received February 12, 2008; accepted May 28, 2008.